natgillin/translations-raw huggingface dataset:
The pharmacokinetic properties of lopinavir co-administered with ritonavir have been evaluated in healthy adult volunteers and in HIV-infected patients; no substantial differences were observed between the two groups.
Farmakokinetične lastnosti lopinavirja, uporabljenega hkrati z ritonavirjem, so ocenili pri zdravih odraslih prostovoljcih in pri bolnikih, okuženih z virusom HIV; med skupinama niso opazili bistvenih razlik.
Do not take Lopinavir/Ritonavir Mylan if: - you are allergic to lopinavir, ritonavir or any of the other ingredients of this medicine (listed in section 6); - you have severe liver problems.
Ne jemljite zdravila Lopinavir/ritonavir Mylan, če: - ste alergični na lopinavir, ritonavir ali katerokoli drugo sestavino tega zdravila (navedeno v poglavju 6); - imate hude težave z jetri.
− The usual adult dose is 400 mg/100 mg twice a day i.e. every 12 hours, in combination with other antiHIV medicines.
- Običajni odmerek za odrasle je 400 mg/100 mg dvakrat na dan, to je vsakih 12 ur, v kombinaciji z drugimi zdravili proti okužbam z virusom HIV.
If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please inform your doctor or pharmacist.
Če katerikoli neželeni učinek postane resen ali če opazite katerikoli neželeni učinek, ki ni omenjen v tem navodilu, obvestite zdravnika ali farmacevta.
The combination may result in increased risk of cardiovascular adverse events associated with salmeterol, including QT prolongation, palpitations and sinus tachycardia.
Kombinacija lahko poveča tveganje za srčno-žilne neželene učinke, povezane s salmeterolom, vključno s podaljšanjem QT, palpitacijami in sinusno tahikardijo.
HIV-1 isolates with reduced susceptibility to lopinavir have been selected in vitro.
Izolati virusa HIV-1 z zmanjšano občutljivostjo za lopinavir so bili izbrani in vitro.
All interaction studies, when otherwise not stated, were performed using lopinavir/ritonavir capsules, which gives an approximately 20% lower exposure of lopinavir than the 200/50 mg tablets.
Vse študije interakcij, če ni drugače navedeno, so bile izvedene z uporabo zdravila lopinavir/ritonavir kapsule, kar pomeni za približno 20 % nižjo izpostavljenost lopinavirju kot pri 200 mg/50 mg tabletah.
Lopinavir/ritonavir has not specifically been tested for its possible effects on the ability to drive a car or operate machines.
Lopinavirja/ritonavirja niso posebej preizkušali glede možnih učinkov na sposobnost za upravljanje vozil ali delo s stroji.
− Breast-feeding mothers should not take lopinavir/ritonavir unless specifically directed by the doctor.
- Doječe matere ne smejo jemati lopinavirja/ritonavirja, razen če jim tega posebej ne naroči zdravnik.
No pattern of birth defects suggestive of a common etiology was seen.
V skupni etilogiji niso opazili vzorca prirojenih napak.
A limited increase in total lopinavir concentrations of approximately 30% has been observed which is not expected to be of clinical relevance (see section 4.2).
Opazili so omejeno povečanje koncentracij lopinavirja za približno 30 %, kar ni pričakovati, da bi bilo klinično pomembno (glejte poglavje 4.2).
− Tell your doctor immediately if you are planning to have a baby, you are pregnant, think you may be pregnant or if you are breast-feeding.
- Zdravniku takoj povejte, če nameravate zanositi, če ste ali če mislite, da bi lahko bili noseči, ali če dojite.
Table 6 Mean (%CV) Steady-State Pharmacokinetic Parameters of Lopinavir in HIV-Infected Pregnant Women
Srednji (% CV) farmakokinetični parametri v stanju ravnovesja za lopinavir pri nosečnicah, okuženih z virusom HIV
Mechanism of action
Mehanizem medsebojnega delovanja
Children less than 2 years of age
Otroci do 2. leta starosti
Lopinavir/ritonavir does not inhibit CYP2D6, CYP2C9, CYP2C19, CYP2E1, CYP2B6 or CYP1A2 at clinically relevant concentrations (see section 4.3).
Lopinavir/ritonavir v klinično pomembnih koncentracijah ne zavira CYP2D6, CYP2C9, CYP2C19, CYP2E1, CYP2B6 ali CYP1A2 (glejte poglavje 4.3).
Outcomes at Week 48: Study M98-863 Lopinavir/ritonavir (N=326)
Rezultati v 48.tednu: Študija M98-863 lopinavir/ritonavir (N=326)
− medicines used to treat pulmonary arterial hypertension (high blood pressure in the pulmonary artery)
- zdravila za zdravljenje pljučne arterijske hipertenzije (visokega krvnega tlaka v pljučni arteriji)
The use of a once daily dosing should be limited to those adult patients having only very few protease inhibitor (PI) associated mutations (i.e. less than 3 PI mutations in line with clinical trial results, see section 5.1 for the full description of the population) and should take into account the risk of a lesser sustainability of the virologic suppression (see section 5.1) and higher risk of diarrhoea (see section 4.8) compared to the recommended standard twice daily dosing.
Uporabo enkrat na dan je treba omejiti na odrasle, ki imajo le zelo malo mutacij, povezanih z zaviralci proteaz (manj kot 3 takšne mutacije v skladu z rezultati klinične študije; za celoten opis populacije glejte poglavje 5.1), in upoštevati je treba tveganje manjše stalnosti virološke supresije (glejte poglavje 5.1) in večje tveganje driske (glejte poglavje 4.8) v primerjavi s priporočeno standardno uporabo dvakrat na dan.
Other forms of this medicine may be more suitable for children; ask your doctor or pharmacist.
Za otroke so morda primernejše druge farmacevtske oblike tega zdravila; posvetujte se z zdravnikom ali framacevtom.
Subsequently, all patients were continued on the 300/75 mg per m2 dose.
Potem so vsi bolniki nadaljevali z odmerkom 300 mg/75 mg na m2.
Within this panel, the following mutations in HIV protease were associated with reduced in vitro susceptibility to lopinavir: L10F/I/R/V, K20M/R, L24I, M46I/L, F53L, I54L/T/V, L63P, A71I/L/T/V, V82A/F/T, I84V and L90M.
V tem okviru so bile z manjšo občutljivostjo za lopinavir in vitro povezane naslednje mutacije proteaze HIV: L10F/I/R/V, K20M/R, L24I, M46I/L, F53L, I54L/T/V, L63P, A71I/L/T/V, V82A/F/T, I84V in L90M.
Paediatric populations
Pediatrična populacija
The safety of lopinavir/ritonavir has been investigated in over 2600 patients in Phase II-IV clinical trials, of which over 700 have received a dose of 800/200 mg (6 capsules or 4 tablets) once daily.
Varnost lopinavirja/ritonavirja so raziskali pri več kot 2600 bolnikih v kliničnih preskušanjih faze II do IV, v katerih jih je preko 700 prejemalo odmerek 800 mg/200 mg (6 kapsul ali 4 tablete) enkrat dnevno.
Voriconazole: Concentrations may be decreased.
vorikonazol vorikonazol: koncentracija se lahko zmanjša.
See section 4.4 and section 4.5 for co-administration of sildenafil in patients with erectile dysfunction.
Glejte poglavje 4.4 in poglavje 4.5 za sočasno uporabo sildenafila pribolnikih zerektilno disfunkcijo.
For patients who have completed the ramp-up phase and are on a steady daily dose of venetoclax, reduce the venetoclax dose by at least 75% when used with strong CYP3A inhibitors (refer to the venetoclax SmPC for dosing instructions).
Za bolnike, ki so zaključili fazo povečevanja odmerka in prejemajo stalen dnevni odmerek venetoklaksa, zmanjšajte dnevni odmerek venetoklaksa za najmanj 75 %, kadar je ta uporabljen z močnimi zaviralci CYP3A (glejte povzetek glavnih značilnosti zdravila za venetoklaks).
Relevant examples are cytomegalovirus retinitis, generalised and/or focal mycobacterial infections, and Pneumocystis jiroveci pneumonia.
Ustrezni primeri so citomegalovirusni retinitis, generalizirane in/ali žariščne okužbe z mikobakterijami in s Pneumocystis jiroveci povzročena pljučnica.
In some patients with advanced HIV infection and a history of opportunistic infection, signs and symptoms of inflammation from previous infections may occur soon after anti-HIV treatment is started.
- Pri bolnikih z napredovalo okužbo z virusom HIV in z zgodovino opurtunistične infekcije se lahko znaki in simptomi vnetja prejšnje infekcije pojavijo kmalu po uvedbi zdravljenja zoper okužbo z virusom HIV.
Lopinavir/ritonavir does this by slowing down the spread of the infection in your body.
Lopinavir/ritonavir to doseže tako, da upočasni širjenje okužbe v telesu.
Sustained virological response to lopinavir/ritonavir (in combination with nucleoside/nucleotide reverse transcriptase inhibitors) has been also observed in a small Phase II study (M97-720) through 360 weeks of treatment.
Dolgotrajni virološki odziv na lopinavirj/ritonavir (v kombinaciji z nukleozidnimi/nukleotidnimi zaviralci reverzne transkriptaze) so ugotovili tudi v majhni študiji faze II (M97-720) med 360 tedni zdravljenja.
Co-administration with other HIV protease inhibitors (PIs) According to current treatment guidelines, dual therapy with protease inhibitors is generally not recommended.
Sočasna uporaba z drugimi zaviralci proteaz HIV (PI) Glede na trenutne terapevtske smernice dvotirno zdravljenje z zaviralci proteaz praviloma ni priporočljivo.
For infants and young children unable to swallow tablets, more suitable formulations containing lopinavir/ritonavir should be checked for their availability.
Za dojenčke in majhne otroke, ki ne morejo pogoltniti tablet, je treba preveriti razpoložljivost primernejše farmacevtske oblike, ki vsebuje lopinavir/ritonavir.
As a general rule, it is recommended that mothers infected by HIV do not breastfeed their babies under any circumstances in order to avoid transmission of HIV.
V splošnem se priporoča, da doječe matere, okužene z virusom HIV, nikakor ne smejo dojiti, da ne pride do prenosa virusa HIV na otroka.
Concomitant Therapy: Efavirenz or nevirapine
Sočasno zdravljenje: efavirenz ali nevirapin
Strong CYP3A4 inhibitors such as protease inhibitors may increase bedaquiline exposure which could potentially increase the risk of bedaquiline related adverse reactions.
Močni zaviralci CYP3A4 kot so zaviralci proteaz lahko povečajo izpostavljenost bedakilinu, kar bi potencialno lahko povečalo tveganje za neželene učinke povezane z bedakilinom.
The safety and efficacy of lopinavir/ritonavir has not been established in patients with significant underlying liver disorders.
Varnost in učinkovitost lopinavirja/ritonavirja nista ugotovljeni pri bolnikih s pomembnimi osnovnimi boleznimi jeter.
Patients with pre-existing liver dysfunction including chronic hepatitis have an increased frequency of liver function abnormalities during combination antiretroviral therapy and should be monitored according to standard practice.
Pri bolnikih z predobstoječo disfunkcijo jeter, vključno s kroničnim hepatitisom, se med kombiniranim protiretrovirusnim zdravljenjem pogosteje pojavljajo nepravilnosti v delovanju jeter, zato jih je treba nadzirati v skladu s standardno prakso.
No subject experienced an increase in QTcF of ≥ 60 ms from baseline or a QTcF interval exceeding the potentially clinically relevant threshold of 500 ms.
Nobenemu preiskovancu se QTcF ni podaljšal za ≥ 60 ms v primerjavi z izhodiščem, dolžina intervala QTcF pa ni pri nobenem presegla potencialno klinično pomembnega praga 500 ms.
You should tell your doctor promptly about these or any other symptoms.
Zdravnika takoj obvestite o neželenih učinkih ali katerihkoli drugih simptomih.
Antipsychotics/ Neuroleptics
Antipsihotiki/ nevroleptiki lurasidon
Further dosage reduction of rifabutin to 150 mg twice weekly on set days is recommended for patients in whom the 150 mg dose 3 times per week is not tolerated.
Nadaljnje zmanjševanje odmerka rifabutina na 150 mg 2-krat na teden ob določenih dnevih je priporočljivo pribolnikih, ki ne prenašajo odmerka 150 mg 3-krat na teden.
− If you are currently using an oral contraceptive or using a patch contraceptive to prevent pregnancy, you should use an additional or different type of contraception (e.g. condom) as lopinavir/ritonavir may reduce the effectiveness of oral and patch contraceptives.
- Če za preprečevanje nosečnosti jemljete peroralne kontraceptive ali kontraceptive v obliki obliža, morate uporabiti dodatno ali drugačno kontracepcijsko zaščito (npr. kondom), kajti lopinavir/ritonavir lahko zmanjša učinkovitost peroralnih kontraceptivov ali kontraceptivov v obliki obliža.
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodium-free'.
To zdravilo vsebuje manj kot 1 mmol natrija (23 mg) na tableto, kar v bistvu pomeni ''brez natrija''.
− Lopinavir/ritonavir should always be taken every day to help control your HIV infection, no matter how much better you feel.
- Da bo lopinavir/ritonavir pomagal obvladovati okužbo z virusom HIV, ga morate vzeti vsak dan, ne glede na to, koliko bolje se počutite.
If you are taking lopinavir/ritonavir once a day
Če jemljete lopinavir/ritonavir enkrat na dan
Increased plasma concentrations of quetiapine which may lead to coma.
Povečana plazemska koncentracija kvetiapina, ki lahko vodi v komo.
− If you realise you have taken more lopinavir/ritonavir than you were supposed to, contact your doctor right away.
- Če ugotovite, da ste vzeli več lopinavirja/ritonavirja, kot bi bilo treba, se takoj posvetujte z zdravnikom.
− Muscle pain, tenderness or weakness, particularly in combination with these medicines.
- Bolečine, občutljivost ali šibkost mišic, zlasti v kombinaciji s protiretrovirusnimi zdravili.
− Lopinavir/ritonavir does not reduce the risk of passing HIV to others.
- Lopinavir/ritonavir ne zmanjša tveganja za prenos okužbe z virusom HIV na druge.
Unless otherwise stated, studies detailed below have been performed with the recommended dosage of lopinavir/ritonavir (i.e. 400/100 mg twice daily).
Če ni navedeno drugače, so bile spodaj omenjene študije opravljene s priporočenim odmerjanjem lopinavirja/ritonavirja (tj. 400 mg/100 mg dvakrat na dan).
− Do not stop or change the daily dose of lopinavir/ritonavir without first consulting with your doctor.
- Dnevnega odmerka lopinavirja/ritonavirja ne opuščajte in ne spreminjajte, ne da bi se prej posvetovali z zdravnikom.
The adequate dosing may be achieved with the two available strengths of lopinavir/ritonavir tablets: 100/25 mg and 200/50 mg.*
Ustrezen odmerek lahko dosežemo z uporabo dveh razpoložljivih jakosti tablet lopinavirja/ritonavirja: 100 mg/25 mg in 200 mg/50 mg.*
The enrolled population was moderately PI-experienced with more than half of patients having never received prior PI and around 80% of patients presenting a viral strain with less than 3 PI mutations.
Vključena populacija je bila zmerno izkušena z zaviralci proteaz: več kot polovica bolnikov ni še nikoli prej dobivalo zaviralce proteaz in približno 80 % bolnikov je imelo virusni sev z manj kot tremi mutacijami, povezanimi z zaviralci proteaz.
Based on the current data available, lopinavir/ritonavir should not be administered once daily in paediatric patients (see section 5.1).
Na podlagi omejenih dosedanjih podatkov, ki so na razpolago, se lopinavirja/ritonavija ne sme odmerjati enkrat na dan pri pediatričnih bolnikih (glejte poglavje 5.1).
(see section 4.5); - riociguat is not recommended (see section 4.5); - vorapaxar is not recommended (see section 4.5); - fusidic acid in osteo-articular infections is not recommended (see section 4.5); - salmeterol is not recommended (see section 4.5); - rivaroxaban is not recommended (see section 4.5).
Kombinacija lopinavirja/ritonavirja s/z: - tadalafilom, uporabljenim za zdravljenje pljučne arterijske hipertenzije, ni priporočljiva (glejte poglavje 4.5); - riociguatom ni priporočljiva (glejte poglavje 4.5); - vorapaksarjem ni priporočljiva (glejte poglavje 4.5); - fusidno kislino pri osteoartikularnih okužbah ni priporočljiva (glejte poglavje 4.5); - salmeterolom ni priporočljiva (glejte poglavje 4.5); - rivaroksabanom ni priporočljiva (glejte poglavje 4.5).
Lopinavir/ritonavir should be prescribed by physicians who are experienced in the treatment of HIV infection.
Lopinavir/ritonavir morajo predpisovati zdravniki, ki imajo izkušnje z zdravljenjem okužbe z virusom HIV.
When Lopinavir/Ritonavir Mylan is administered concomitantly with bosentan, the efficacy of the HIV therapy should be monitored and patients should be closely observed for bosentan toxicity, especially during the first week of coadministration.
Če je zdravilo Lopinavir/ritonavir Mylan uporabljeno sočasno z bosentanom, je treba učinkovitost zdravljenja HIV kontrolirati, bolnike pa skrbno opazovati glede toksičnosti bosentana, zlasti prvi teden sočasne uporabe.
The percentage of patients with confirmed viral rebound ≥50 copies/ml during 48 weeks of follow-up was higher in the paediatric patients receiving lopinavir/ritonavir tablets once daily (12%) than in patients receiving the twice-daily dosing (8%, p = 0.19), mainly due to lower adherence in the once-daily group.
Odstotek bolnikov s potrjenim virusnim preobratom ≥ 50 kopij/ml v obdobju 48 tednov spremljanja je bil večji pri pediatričnih bolnikih, ki so prejemali lopinavir/ritonavir tablete enkrat na dan (12 %) kot pri bolnikih, ki so prejemali odmerek dvakrat na dan (18 %, p = 0.19), zlasti zaradi manjšega sodelovanja bolnikov v skupini, ki je prejemala odmerek enkrat na dan.
Amprenavir concentrations are significantly reduced.
fosamprenavir: koncentracija amprenavirja se bistveno zmanjša.
If the benefit is considered to outweigh the risk and Lopinavir/Ritonavir Mylan must be used, reduce the ibrutinib dose to 140 mg and monitor patient closely for toxicity.
Če korist odtehta tveganje in je treba zdravilo Lopinavir/ritonavir Mylan uporabiti, zmanjšajte odmerek ibrutiniba na 140 mg in pozorno spremljate bolnika za toksičnost.
Lopinavir/ritonavir has been shown in vivo to induce its own metabolism and to increase the biotransformation of some medicinal products metabolised by cytochrome P450 enzymes (including CYP2C9 and CYP2C19) and by glucuronidation.
In vivo je bilo dokazano, da lopinavir/ritonavir inducira svojo lastno presnovo in zvečuje biotransformacijo nekaterih zdravil, ki se presnavljajo z encimi citokroma P450 (vključno s CYP2C9 in CYP2C19) in z glukuronidacijo.
M98-940 was an open-label study of a liquid formulation of lopinavir/ritonavir in 100 antiretroviral naïve (44%) and experienced (56%) paediatric patients.
M98-940 je odprta študija tekočega pripravka lopinavirja/ritonavirja pri 100 protiretrovirusno nezdravljenih (44 %) in izkušenih (56 %) pediatričnih bolnikih.
Like all medicines, lopinavir/ritonavir can cause side effects, although not everybody gets them.
Kot vsa zdravila ima lahko tudi lopinavir/ritonavir neželene učinke, ki pa se ne pojavijo pri vseh bolnikih.
Antiarrhythmics Amiodarone, Dronedarone
Antiaritmiki amiodaron, dronedaron
− If a side effect is preventing you from taking lopinavir/ritonavir as directed tell your doctor right away.
- Če vam neželen učinek prepreči, da bi lopinavir/ritonavir jemali, kot vam je bilo naročeno, to takoj povejte zdravniku.
If you are taking lopinavir/ritonavir twice a day
Če jemljete lopinavir/ritonavir dvakrat na dan
Not applicable.
Navedba ni primerna.
2 tablets (200/50 mg)
2 tableti (200 mg/50 mg)
A dose reduction of the glucocorticoid should be considered with close monitoring of local and systemic effects or a switch to a glucocorticoid, which is not a substrate for CYP3A4 (e.g. beclomethasone).
V poštev pride zmanjšanje glukokortikoida (ob tem je treba natančno kontrolirati lokalne in sistemske učinke), ali prehod na glukokortikoid, ki ni substrat CYP3A4 (npr. beklometazon).
Particular caution must be used when prescribing lopinavir/ritonavir and medicinal products known to induce QT interval prolongation such as: chlorpheniramine, quinidine, erythromycin, clarithromycin.
Posebna previdnost je potrebna pri predpisovanju lopinavirja/ritonavirja in zdravil, ki podaljšujejo interval QT; takšna so npr. klorfeniramin, kinidin, eritromicin, klaritromicin.
The median EC50 of lopinavir against isolates with 0 − 3, 4 − 5, 6 − 7 and 8 − 10 mutations at the above amino acid positions was 0.8, 2.7, 13.5 and 44.0-fold higher than the EC50 against wild type HIV, respectively.
Mediana EC50 lopinavirja proti izolatom z 0-3, 4-5, 6-7 oz. 8-10 mutacijami na omenjenih aminokislinskih položajih je bila 0,8-, 2,7-, 13,5- oz. 44,0-krat večja kot EC50 proti divjemu tipu HIV.
Recommended number of 100/25 mg tablets twice-daily
Priporočeno število 100 mg/25 mg tablet dvakrat na dan
Before prescribing lopinavir/ritonavir 100/25 mg tablets, infants and young children should be assessed for the ability to swallow intact tablets.
Pred predpisovanjem 100 mg/25 mg tablet z lopinavirjem/ritonavirjem, je potrebno pri dojenčkih in mlajših otrocih oceniti sposobnost požiranja celih tablet.
It is unknown whether the combination of Lopinavir/Ritonavir Mylan causes a similar increase in trazodone exposure.
Ni znano, ali tudi kombinacija zdravila Lopinavir/ritonavir Mylan podobno poveča izpostavljenost trazodonu.
The effective (peak to trough) half-life of lopinavir over a 12 hour dosing interval averaged 5 - 6 hours, and the apparent oral clearance (CL/F) of lopinavir is 6 to 7 l /h.
Efektivni (od vrha do dna) razpolovni čas lopinavirja v 12-urnem odmernem intervalu je bil v povprečju od 5 do 6 ur, navidezni peroralni očistek (CL/F) lopinavirja pa je 6 do 7 l/h.
Other side effects that have been reported with lopinavir/ritonavir: yellowing of the skin or whites of eyes (jaundice), severe or life threatening skin rashes and blisters (Stevens-Johnson syndrome and erythema multiforme).
Drugi neželeni učinki, o katerih so poročali pri lopinavirju/ritonavirju so: porumenitev kože ali očesnih beločnic (zlatenica), hudi ali življenje-ogrožujoči izpuščaji in mehurji (Stevens-Johnsonov sindrom in multiformni eritem).
A 14C-lopinavir study in humans showed that 89% of the plasma radioactivity after a single 400/100 mg lopinavir/ritonavir dose was due to parent active substance.
Študija s 14C-lopinavirjem pri ljudeh je pokazala, da gre 89 % radioaktivnosti v plazmi po enkratnem odmerku 400 mg/100 mg lopinavirja/ritonavirja na račun matične zdravilne učinkovine.
Ranitidine: ↔
ranitidin: ↔
Adequate exposure to lopinavir/ritonavir may be achieved when a higher dose of lopinavir/ritonavir is used but this is associated with a higher risk of liver and gastrointestinal toxicity.
Zadostno izpostavljenost kombinaciji lopinavir/ritonavir se lahko doseže z uporabo višjega odmerka lopinavirja/ritonavirja, vendar je to povezano z večjim tveganjem za jetrno in gastrointestinalno toksičnost.
The choice of lopinavir/ritonavir to treat protease inhibitor experienced HIV-1 infected patients should be based on individual viral resistance testing and treatment history of patients (see sections 4.4 and 5.1).
Izbira lopinavirja/ritonavirja za zdravljenje s HIV-1 okuženih in z zaviralci proteaz izkušenih bolnikov mora temeljiti na individualnem preizkusu odpornosti virusa in anamnezi bolnikovega zdravljenja (glejte poglavji 4.4 in 5.1).
Therefore, Lopinavir/Ritonavir Mylan can be started safely 2 weeks after cessation of St John's wort.
Zato je zdravilo Lopinavir/ritonavir Mylan mogoče varno začeti uporabljati 2 tedna po prenehanju jemanja šentjanževke.
Difference [95% CI]
Razlik a [95 % IZ]
Tadalafil:
tadalafil tadalafil:
Based on known metabolic profiles, clinically significant interactions are not expected between Lopinavir/Ritonavir Mylan and dapsone, trimethoprim/sulfamethoxazole, azithromycin or fluconazole.
Na temelju znanih presnovnih značilnosti ni pričakovati klinično pomembnega medsebojnega delovanja zdravila Lopinavir/ritonavir Mylan in dapsona, trimetoprima/sulfametoksazola, azitromicina ali flukonazola.
If Lopinavir/Ritonavir Mylan is coadministered with parenteral midazolam, it should be done in an intensive care unit (ICU) or similar setting which ensures close clinical monitoring and appropriate medical management in case of respiratory depression and/or prolonged sedation.
Če je zdravilo Lopinavir/ritonavir Mylan uporabljeno sočasno s parenteralnim midazolamom, je to potrebno izvesti v enoti za intenzivno nego (EIN) ali podobnem okolju, ki omogoča natančno kliničen nadzor in ustrezno medicinsko ukrepanje v primeru depresije dihanja in/ali dolgotrajne sedacije.
While rosuvastatin is poorly metabolised by CYP3A4, an increase of its plasma concentrations was observed.
Ker se rosuvastatin slabo presnavlja s CYP3A4, so opažali povečanje koncentracije v plazmi.
400/100 mg 500/125 mg
400 mg/100 mg 500 mg/125 mg